About Aegera Therapeutics
Aegera Therapeutics is a company based in Montreal (Canada) founded in 2000 was acquired by PharmaScience in May 2011. Aegera Therapeutics has raised $37.9 million across 5 funding rounds from investors including Desjardins, PharmaScience and BDC. Aegera Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Montreal, Canada
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$37.9 M (USD)
in 5 rounds
-
Latest Funding Round
$6.53 M (USD), Debt – Conventional
Sep 23, 2009
-
Investors
Desjardins
& 11 more
-
Employee Count
Not available
-
Acquired by
PharmaScience
(May 27, 2011)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Aegera Therapeutics
Aegera Therapeutics has successfully raised a total of $37.9M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $6.53 million completed in September 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aegera Therapeutics
Aegera Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Desjardins, PharmaScience and BDC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity buyouts are targeted by the investment firm.
|
Locked | Locked | Locked | |
|
Stage-agnostic sector-agnostic VC firm investing in Canada and the US
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Aegera Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aegera Therapeutics
Investment portfolio details for Aegera Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aegera Therapeutics
Detailed financials for Aegera Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aegera Therapeutics Comparisons
Peer comparison for Aegera Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aegera Therapeutics
Aegera Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Aegera Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aegera Therapeutics
Complete news archive for Aegera Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aegera Therapeutics
Aegera Therapeutics was founded in 2000 and raised its 1st funding round 2 years after it was founded.
Aegera Therapeutics is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Aegera Therapeutics is a funded company, having raised a total of $37.9M across 5 funding rounds to date.
Aegera Therapeutics, part of Pharmascience, is focused on developing targeted therapeutics to address major unmet medical needs. Aegera focuses on preclinical and early-stage clinical development through integration of in-house medicinal chemistry, biochemistry, cell biology, pharmacokinetics and in vivo pharmacologyefficacy. Aegera has one oncology program in clinical development and several preclinical programs. HGS1029 is a small molecule pan-IAP inhibitor that has demonstrated very promising preclinical activity across a broad range of cancers. A license and collaboration agreement was completed in December 2007 with Human Genome Sciences and HGS1029 is currently progressing in Phase 1 - solid tumor study. Aegera has several preclinical stage programs targeting key proteins involved in oncology and autoimmuneinflammatory diseases, including a small molecule Brutons tyrosine kinase (Btk) inhibitor program.
Aegera Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Aegera Therapeutics has 12 investors. Key investors include Desjardins, PharmaScience, BDC, Invest Quebec, and VenGrowth VG Partners.